Therapeutic approaches to spinal and bulbar muscular atrophy

Trends in Pharmacological Sciences

Volumn 31, Issue 11, 2010, Pages 523-527

  Ranganathan, Srikanth ^a   Fischbeck, Kenneth H ^b  

^a LUND UNIVERSITY   (Sweden)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 DEMETHOXY 17 (2 DIMETHYLAMINOETHYLAMINO)GELDANAMYCIN; ANDROGEN RECEPTOR; ANTIANDROGEN; ASC J9; BUTYRIC ACID; CYCLOSPORIN A; DUTASTERIDE; FLUTAMIDE; HEAT SHOCK PROTEIN 90; IDEBENONE; LEUPRORELIN; PLACEBO; SEX HORMONE ANTAGONIST; SOMATOMEDIN C; TANESPIMYCIN; TESTOSTERONE; UBIQUINONE; UNCLASSIFIED DRUG; VASCULOTROPIN;

CASTRATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG MECHANISM; DRUG RESPONSE; EXERCISE; GENE MUTATION; HUMAN; KENNEDY DISEASE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW;

ANDROGEN ANTAGONISTS; ANIMALS; FEMALE; GENE EXPRESSION REGULATION; HSP90 HEAT-SHOCK PROTEINS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; MALE; MICE; MICE, TRANSGENIC; MOLECULAR CHAPERONES; MOTOR NEURON DISEASE; MUSCULAR ATROPHY, SPINAL; MUTATION; RECEPTORS, ANDROGEN; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 77958150581     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2010.08.005     Document Type: Review

References (41)

1. Finsterer J. Bulbar and spinal muscular atrophy (Kennedy's disease): a review. Eur. J. Neurol. 2009, 16:556-561.
2. Beitel L.K., et al. Progress in spinobulbar muscular atrophy research: insights into neuronal dysfunction caused by the polyglutamine-expanded androgen receptor. Neurotox. Res. 2005, 7:219-230.
3. Rhodes L.E., et al. Clinical features of spinal and bulbar muscular atrophy. Brain 2009, 132:3242-3251.
4. Sopher B.L., et al. Androgen receptor YAC transgenic mice recapitulate SBMA motor neuronopathy and implicate VEGF164 in the motor neuron degeneration. Neuron 2004, 41:687-699.
5. Chevalier-Larsen E.S., et al. Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy. J. Neurosci. 2004, 24:4778-4786.
6. Yamada M., et al. CAG repeat disorder models and human neuropathology: similarities and differences. Acta Neuropathol. 2008, 115:71-86.
7. Yu Z., et al. Androgen-dependent pathology demonstrates myopathic contribution to the Kennedy disease phenotype in a mouse knock-in model. J. Clin. Invest. 2006, 116:2663-2672.
8. Tokui K., et al. 17-DMAG ameliorates polyglutamine-mediated motor neuron degeneration through well-preserved proteasome function in an SBMA model mouse. Hum. Mol. Genet. 2009, 18:898-910.
9. Yang Z.M., et al. ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor. Nat. Med. 2007, 13:348-353.
10. Palazzolo I., et al. The role of the polyglutamine tract in androgen receptor. J. Steroid Biochem. Mol. Biol. 2008, 108:245-253.
11. Adachi H., et al. Pathogenesis and molecular targeted therapy of spinal and bulbar muscular atrophy. Neuropathol. Appl. Neurobiol. 2007, 33:135-151.
12. Katsuno M., et al. Pathogenesis, animal models and therapeutics in spinal and bulbar muscular atrophy (SBMA). Exp. Neurol. 2006, 200:8-18.
13. Becker M., et al. Cytoplasmic localization and the choice of ligand determine aggregate formation by androgen receptor with amplified polyglutamine stretch. J. Cell Biol. 2000, 149:255-262.
14. Stenoien D.L., et al. Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone. Hum. Mol. Genet. 1999, 8:731-741.
15. Schmidt B.J., et al. Expression of X-linked bulbospinal muscular atrophy (Kennedy disease) in two homozygous women. Neurology 2002, 59:770-772.
16. Banno H., et al. Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. Ann. Neurol. 2009, 65:140-150.
17. Katsuno M., et al. Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010, 9:875-884.
18. Banno H., et al. Neuropathology and therapeutic intervention in spinal and bulbar muscular atrophy. Int. J. Mol. Sci. 2009, 10:1000-1012.
19. Li M., et al. Soluble androgen receptor oligomers underlie pathology in a mouse model of spinobulbar muscular atrophy. J. Biol. Chem. 2007, 282:3157-3164.
20. Howarth J.L., et al. Hsp40 molecules that target to the ubiquitin-proteasome system decrease inclusion formation in models of polyglutamine disease. Mol. Ther. 2007, 15:1100-1105.
21. Waza M., et al. Modulation of Hsp90 function in neurodegenerative disorders: a molecular-targeted therapy against disease-causing protein. J. Mol. Med. 2006, 84:635-646.
22. Waza M., et al. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat. Med. 2005, 11:1088-1095.
23. Bennett E.J., et al. Global changes to the ubiquitin system in Huntington's disease. Nature 2007, 448:704-708.
24. Adachi H., et al. CHIP overexpression reduces mutant androgen receptor protein and ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model. J. Neurosci. 2007, 27:5115-5126.
25. Maynard C.J., et al. Accumulation of ubiquitin conjugates in a polyglutamine disease model occurs without global ubiquitin/proteasome system impairment. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:13986-13991.
26. Holzbeierlein J.M., et al. Hsp90: a drug target?. Curr. Oncol. Rep. 2010, 12:95-101.
27. Katsuno M., et al. Reversible disruption of dynactin 1-mediated retrograde axonal transport in polyglutamine-induced motor neuron degeneration. J. Neurosci. 2006, 26:12106-12117.
28. Morfini G., et al. JNK mediates pathogenic effects of polyglutamine-expanded androgen receptor on fast axonal transport. Nat. Neurosci. 2006, 9:907-916.
29. Palazzolo I., et al. Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy. Neuron 2009, 63:316-328.
30. Palazzolo I., et al. Akt blocks ligand binding and protects against expanded polyglutamine androgen receptor toxicity. Hum. Mol. Genet. 2007, 16:1593-1603.
31. Boutillier A.-L., et al. Chromatin acetylation status in the manifestation of neurodegenerative diseases: HDAC inhibitors as therapeutic tools. Subcell. Biochem. 2007, 41:263-293.
32. Hahnen E., et al. Histone deacetylase inhibitors: possible implications for neurodegenerative disorders. Expert Opin. Invest. Drugs 2008, 17:169-184. PMID 18230051.
33. McCampbell A., et al. CREB-binding protein sequestration by expanded polyglutamine. Hum. Mol. Genet. 2000, 9:2197-2202.
34. Arndt V., et al. Chaperone-assisted selective autophagy is essential for muscle maintenance. Curr. Biol. 2010, 20:143-148.
35. Crippa V., et al. The small heat shock protein B8 (HspB8) promotes autophagic removal of misfolded proteins involved in amyotrophic lateral sclerosis (ALS). Hum. Mol. Genet. 2010, 19:3440-3456.
36. Montie H.L., et al. Cytoplasmic retention of polyglutamine-expanded androgen receptor ameliorates disease via autophagy in a mouse model of spinal and bulbar muscular atrophy. Hum. Mol. Genet. 2009, 18:1937-1950.
37. Ranganathan S., et al. Mitochondrial abnormalities in spinal and bulbar muscular atrophy. Hum. Mol. Genet. 2009, 18:27-42.
38. Di Prospero N.A., et al. Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial. Lancet Neurol. 2007, 6:878-886.
39. Drinkard B.E., et al. Exercise capacity and idebenone intervention in children and adolescents with Friedreich ataxia. Arch. Phys. Med. Rehabil. 2010, 91:1044-1050.
40. Rustin P., et al. Heart hypertrophy and function are improved by idebenone in Friedreich's ataxia. Free Radic. Res. 2002, 36:467-469.
41. Preisler N., et al. Effect of aerobic training in patients with spinal and bulbar muscular atrophy (Kennedy disease). Neurology 2009, 72:317-323.